Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma

被引：49
|
作者：
Ortega, Hector [1 ]
Katz, Lynn [1 ]
Gunsoy, Necdet [2 ]
Keene, Oliver [2 ]
Yancey, Steven [1 ]
机构：
[1] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline, Clin Stat, Stockley Pk, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 136卷 / 03期
关键词：
MEPOLIZUMAB;
D O I：
10.1016/j.jaci.2015.05.039
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：825 / +
页数：2
相关论文
共 50 条
  • [1] Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma
    Corren, Jonathan
    Du, Evelyn
    Gubbi, Ananda
    Vanlandingham, Rebecca
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03): : 1224 - +
  • [2] High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma
    Fowler, Stephen J.
    Tavernier, Gael
    Niven, Robert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (03) : 822 - 824
  • [3] Blood Eosinophil Phenotype During Treatment With Mepolizumab in Patients With Severe Eosinophilic Asthma
    Sakai, C.
    Matsuyama, M.
    Nakajima, M.
    Matsumura, S.
    Nonaka, M.
    Arai, N.
    Kuramoto, K.
    Yoshida, K.
    Morishima, Y.
    Muratani, M.
    Hizawa, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [4] Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
    Sakai, Chio
    Matsuyama, Masashi
    Nakajima, Masayuki
    Matsumura, Sosuke
    Nonaka, Mizu
    Arai, Naoki
    Kuramoto, Kenya
    Yoshida, Kazufumi
    Morishima, Yuko
    Muratani, Masafumi
    Hizawa, Nobuyuki
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (03) : 473 - 476
  • [5] GREATER EFFICACY OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA WITH HIGH BASELINE BLOOD EOSINOPHIL COUNTS
    Silver, J.
    Llanos, J.
    Mayer, B.
    Prazma, C.
    Albers, F.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S37 - S38
  • [6] Blood eosinophil subtype distribution following treatment with mepolizumab in patients with severe eosinophilic asthma
    Rimkunas, Airidas
    Januskevicius, Andrius
    Vasyle, Egle
    Palacionyte, Jolita
    Jermalaviciene, Inesa
    Miliauskas, Skaidrius
    Malakauskas, Kestutis
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [7] Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma
    Bleecker, Eugene R.
    Meyers, Deborah A.
    Billheimer, Dean
    Li, Huashi
    Newbold, Paul
    Kwiatek, Justin
    Hirsch, Ian
    Katial, Rohit
    Li, Xingnan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2023, 11 (06): : 1805 - 1813
  • [8] Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma
    Albers, Frank C.
    Licskai, Christopher
    Chanez, Pascal
    Bratton, Daniel J.
    Bradford, Eric S.
    Yancey, Steven W.
    Kwon, Namhee
    Quirce, Santiago
    RESPIRATORY MEDICINE, 2019, 159
  • [9] Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma
    Ortega, Hector
    Katz, Lynn
    Hartley, Benjamin
    Yancey, Steve
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [10] Blood Eosinophil Count and Fractional Exhaled Nitric Oxide as a Combined Predictor of Treatment Response to Benralizumab for Patients with Severe, Eosinophilic Asthma
    Katial, R.
    Kreindler, J.
    Hirsch, I
    Newbold, P.
    Gil, Garcia E. G.
    PNEUMOLOGIE, 2021, 75 : S34 - S34
12345